Juan Carlos Garca-Caaveras

List of Publications by Year in Descending Order

33 papers	1,210 citations	18 h-index	34 g-index
35 ext. papers	1,771 ext. citations	11.2 avg, IF	4.73 L-index

#	Paper	IF	Citations
33	MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function. *Immunity*, **2021**,	32.3	7
32	Tumor Microenvironment-Derived Metabolites: A Guide to Find New Metabolic Therapeutic Targets and Biomarkers. *Cancers*, **2021**, 13,	6.6	4
31	SHMT inhibition is effective and synergizes with methotrexate in T-cell acute lymphoblastic leukemia. *Leukemia*, **2021**, 35, 377-388	10.7	26
30	Reviewing the metabolome coverage provided by LC-MS: Focus on sample preparation and chromatography-A tutorial. *Analytica Chimica Acta*, **2021**, 1147, 38-55	6.6	11
29	c-MYC Triggers Lipid Remodelling During Early Somatic Cell Reprogramming to Pluripotency. *Stem Cell Reviews and Reports*, **2021**, 17, 2245-2261	7.3	0
28	CAR T-Cells Depend on the Coupling of NADH Oxidation with ATP Production. *Cells*, **2021**, 10,	7.9	1
27	Novel media formulations to enhance Chimeric Antigen Receptor (CAR) T-cell potency and anti-tumor cell function for adoptive immunotherapy. *Cytotherapy*, **2020**, 22, S133	4.8	2
26	Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity. *Cell*, **2020**, 183, 1848-1866.e26	56.2	112
25	A small molecule G6PD inhibitor reveals immune dependence on pentose phosphate pathway. *Nature Chemical Biology*, **2020**, 16, 731-739	11.7	29
24	Serine Catabolism Feeds NADH when Respiration Is Impaired. *Cell Metabolism*, **2020**, 31, 809-821.e6	24.6	58
23	Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8 T cell stemness and antitumor immunity. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 6047-6055	11.5	57
22	Enhancing Chimeric Antigen Receptor T Cell Anti-tumor Function through Advanced Media Design. *Molecular Therapy - Methods and Clinical Development*, **2020**, 18, 595-606	6.4	14
21	Endothelin-1-Mediated Drug Resistance in -Mutant Non-Small Cell Lung Carcinoma. *Cancer Research*, **2020**, 80, 4224-4232	10.1	4
20	Chaperone-mediated autophagy regulates the pluripotency of embryonic stem cells. *Science*, **2020**, 369, 397-403	33.3	26
19	Distinct modes of mitochondrial metabolism uncouple T cell differentiation and function. *Nature*, **2019**, 571, 403-407	50.4	86
18	The Tumor Metabolic Microenvironment: Lessons from Lactate. *Cancer Research*, **2019**, 79, 3155-3162	10.1	66
17	Sparse N-way partial least squares by L1-penalization. *Chemometrics and Intelligent Laboratory Systems*, **2019**, 185, 85-91	3.8	5

#	Publication	IF	Cit.
16	LipidMS: An R Package for Lipid Annotation in Untargeted Liquid Chromatography-Data Independent Acquisition-Mass Spectrometry Lipidomics. *Analytical Chemistry*, **2019**, 91, 836-845	7.8	19
15	PPARᵧ is a nexus controlling alternative activation of macrophages via glutamine metabolism. *Genes and Development*, **2018**, 32, 1035-1044	12.6	51
14	A lipidomic cell-based assay for studying drug-induced phospholipidosis and steatosis. *Electrophoresis*, **2017**, 38, 2331-2340	3.6	12
13	RpeakChrom: Novel R package for the automated characterization and optimization of column efficiency in high-performance liquid chromatography analysis. *Electrophoresis*, **2017**, 38, 2985-2995	3.6	3
12	Liver Transplantation Biomarkers in the Metabolomics Era. *Biomarkers in Disease*, **2017**, 99-128		1
11	Extending metabolome coverage for untargeted metabolite profiling of adherent cultured hepatic cells. *Analytical and Bioanalytical Chemistry*, **2016**, 408, 1217-30	4.4	28
10	Liver Transplantation Biomarkers in the Metabolomics Era. *Biomarkers in Disease*, **2016**, 1-29		
9	A metabolomics cell-based approach for anticipating and investigating drug-induced liver injury. *Scientific Reports*, **2016**, 6, 27239	4.9	50
8	LC-MS untargeted metabolomic analysis of drug-induced hepatotoxicity in HepG2 cells. *Electrophoresis*, **2015**, 36, 2294-2302	3.6	25
7	In vitro/in vivo screening of oxidative homeostasis and damage to DNA, protein, and lipids using UPLC/MS-MS. *Analytical and Bioanalytical Chemistry*, **2014**, 406, 5465-76	4.4	17
6	Ultra-performance liquid chromatography-mass spectrometry targeted profiling of bile acids: application to serum, liver tissue, and cultured cells of different species. *Methods in Molecular Biology*, **2014**, 1198, 233-47	1.4	6
5	Metabolomics discloses donor liver biomarkers associated with early allograft dysfunction. *Journal of Hepatology*, **2014**, 61, 564-74	13.4	49
4	Mammalian cell metabolomics: experimental design and sample preparation. *Electrophoresis*, **2013**, 34, 2762-75	3.6	130
3	Chemometric approaches to improve PLSDA model outcome for predicting human non-alcoholic fatty liver disease using UPLC-MS as a metabolic profiling tool. *Metabolomics*, **2012**, 8, 86-98	4.7	47
2	Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method. *Journal of Lipid Research*, **2012**, 53, 2231-2241	6.3	171
1	A comprehensive untargeted metabonomic analysis of human steatotic liver tissue by RP and HILIC chromatography coupled to mass spectrometry reveals important metabolic alterations. *Journal of Proteome Research*, **2011**, 10, 4825-34	5.6	93